Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Cerecor (CERC) Receives a Buy from Oppenheimer
08:47am, Friday, 27'th Mar 2020
Oppenheimer analyst Leland Gershell maintained a Buy rating on Cerecor (CERC) today and set a price target of $11.00. The company's shares closed last
Cerecor (CERC) Receives a Buy from Oppenheimer
08:47am, Friday, 27'th Mar 2020
Oppenheimer analyst
Leland Gershell
maintained a
Buy
rating on Cerecor (
CERC
–
Research Report
) today and set a price target of
$11.00
. The company’s shares closed last Monday at $2.61.
Accordi
Corbus Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CRBP)
06:24am, Friday, 27'th Mar 2020
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) was the recipient of some unusual options trading activity on Thursday. Stock traders purchased 2,593 call options on the stock. This represents an in
Cannabis Central: Sector Down 45% YTD With Only These 2 Pot Stocks Increasing In Price
09:06pm, Thursday, 26'th Mar 2020
The non-penny pot stock sector of 37 stocks is down 22% YTD which, as terrible as that certainly is, is better than the cannabis sector as a whole (319 stocks) which is down 46% YTD. This article ide
Fly Intel: Top five analyst initiations INTU;WMT;CRBP;DD;BDC
02:48pm, Thursday, 26'th Mar 2020
Fly Intel: Top five analyst initiations INTU WMT CRBP DD BDC
RBC sees 21% upside in Danaher in premarket analyst action
11:23am, Thursday, 26'th Mar 2020
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) initiated with Buy rating and $12 (143% upside) price target at Nomura Instinet.Bruker (NASDAQ:BRKR) upgraded to Overweight with a $48 (31% upside) price
Corbus Pharmaceuticals initiated with a Buy at Nomura Instinet CRBP
10:33am, Thursday, 26'th Mar 2020
Corbus Pharmaceuticals initiated with a Buy at Nomura Instinet Nomura Instinet CRBP
In Biotech ‘Cash Is King’ When Wall Street Searches for Value
06:04pm, Wednesday, 25'th Mar 2020
(Bloomberg) -- For investors looking for deals in biotech, Wall Street firms like Baird advise “cash is king.”Losses in the U.S. stock market have decimated many portfolios. And while biotechnolog
Analysts Offer Insights on Healthcare Companies: Agile Therapeutics (AGRX) and Vir Biotechnology (VIR)
02:21pm, Wednesday, 25'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agile Therapeutics (AGRX) and Vir Biotechnology (VIR) with
Analysts Offer Insights on Healthcare Companies: Agile Therapeutics (NASDAQ: AGRX) and Vir Biotechnology (NASDAQ: VIR)
02:21pm, Wednesday, 25'th Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agile Therapeutics (
AGRX
–
Research Report
) and Vir Biotechnology (
VIR
–
Research Report
) with
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Holdings Lifted by Bank of Montreal Can
10:06am, Wednesday, 25'th Mar 2020
Bank of Montreal Can lifted its stake in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) by 16.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission
Cannabis Central: Sector Was Up Tuesday For 4th Consecutive Day By 8.4%
08:56am, Wednesday, 25'th Mar 2020
Despite the turmoil in the stock market the 8.4% increase in the pot stock sector on Tuesday was the fourth consecutive day of positive returns which begs the question:
Analyst Explains Why They Downgraded Their Rating on Milestone Pharmaceuticals (MIST)
11:36am, Tuesday, 24'th Mar 2020
In a report released today, Leland Gershell from Oppenheimer downgraded Milestone Pharmaceuticals (MIST) to Hold. The company's shares closed last Monday
Analyst Explains Why They Downgraded Their Rating on Milestone Pharmaceuticals (MIST)
11:36am, Tuesday, 24'th Mar 2020
In a report released today,
Leland Gershell
from Oppenheimer downgraded Milestone Pharmaceuticals (
MIST
–
Research Report
) to
Hold
. The company’s shares closed last Monday at $14.00.
According
Cannabis Central: Sector Held Its Own On Monday With Advances Exceeding Declines
09:16am, Tuesday, 24'th Mar 2020
The cannabis stock sector held its own on Monday (+0.5%) with 23 of the 37 non-penny stocks advancing and 14 of said stocks declining.
